Unnamed: 0,title,date,stock,sentiment
171898.0,BioLineRx Announces $4.39 Million Registered Direct Offering,2020-06-01 08:19:00-04:00,BLRX,neutral
171899.0,96 Biggest Movers From Yesterday,2020-05-27 04:20:00-04:00,BLRX,neutral
171900.0,Mid-Afternoon Market Update: Crude Oil Up 2%; argenx Shares Spike Higher,2020-05-26 14:32:00-04:00,BLRX,negative
171901.0,61 Stocks Moving In Tuesday's Mid-Day Session,2020-05-26 12:29:00-04:00,BLRX,neutral
171902.0,Mid-Day Market Update: Dow Jumps Over 600 Points; BioLineRx Shares Plunge,2020-05-26 12:21:00-04:00,BLRX,positive
171903.0,Mid-Morning Market Update: Markets Open Higher; AutoZone Beats Q3 Expectations,2020-05-26 10:16:00-04:00,BLRX,neutral
171904.0,BioLineRx Announces $9M Registered Direct Offering,2020-05-26 08:43:00-04:00,BLRX,neutral
171905.0,71 Biggest Movers From Friday,2020-05-26 04:30:00-04:00,BLRX,neutral
171906.0,46 Stocks Moving In Friday's Mid-Day Session,2020-05-22 12:45:00-04:00,BLRX,neutral
171907.0,BioLine Rx Q1 EPS $(0.040) Beats $(0.660) Estimate,2020-05-20 07:09:00-04:00,BLRX,neutral
171908.0,BioLineRx Shares Tick Slightly Higher On Uptick In Volume; Traders Circulate Apr. 23-Dated World Intellectual Property Organization PatentScope Doc For 'Treatment Of Metastatic Pancreatic Adenocarcinoma',2020-04-23 10:49:00-04:00,BLRX,positive
171909.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-04-13 07:39:00-04:00,BLRX,neutral
171910.0,BioLineRx Reports Notice Of Allowance Of US PTO For Patent Covering BL-8040 In Combo With Anti-PD-1 For Treatment Of Any Type Of Cancer,2020-02-27 07:45:00-05:00,BLRX,negative
171911.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,BLRX,neutral
171912.0,9 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-22 07:33:00-05:00,BLRX,neutral
171913.0,6 Biotechnology Stocks Moving In Wednesday's Pre-Market Session,2020-01-22 07:33:00-05:00,BLRX,neutral
171914.0,BioLineRx Completes Recruitment In Triple Combination Arm Of COMBAT/KEYNOTE-202 Study In Patients With Second-line Metastatic Pancreatic Cancer,2020-01-22 07:06:00-05:00,BLRX,negative
171915.0,BioLineRx Receives Orphan Drug Designation For Motixafortide (BL-8040) For Treatment Of Pancreatic Cancer In Europe,2020-01-14 07:12:00-05:00,BLRX,negative
171916.0,74 Biggest Movers From Yesterday,2019-12-17 05:35:00-05:00,BLRX,neutral
171917.0,40 Stocks Moving In Monday's Mid-Day Session,2019-12-16 12:10:00-05:00,BLRX,neutral
171918.0,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer",2019-12-13 08:10:00-05:00,BLRX,positive
171919.0,BioLineRx Offers Updated Phase 2a Data From Triple Combo Arm Of COMBAT/KEYNOTE-202 Study In Patients With Second-line Metastatic Pancreatic Cancer,2019-12-13 07:07:00-05:00,BLRX,negative
171920.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,BLRX,neutral
171921.0,74 Biggest Movers From Friday,2019-12-09 05:22:00-05:00,BLRX,neutral
171922.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,BLRX,positive
171923.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,BLRX,positive
171924.0,75 Biggest Movers From Yesterday,2019-12-06 05:36:00-05:00,BLRX,neutral
171925.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-12-05 12:07:00-05:00,BLRX,neutral
171926.0,Stocks That Hit 52-Week Lows On Thursday,2019-12-05 10:33:00-05:00,BLRX,negative
171927.0,Mid-Morning Market Update: Markets Open Lower; Dollar General Earnings Top Expectations,2019-12-05 10:13:00-05:00,BLRX,negative
171928.0,BioLineRx Reports Prelim. Phase 2a Data From Triple Combo Arm Of COMBAT/KEYNOTE-202 Study In Second-Line Patients With Metastatic Pancreatic Cancer,2019-12-05 07:31:00-05:00,BLRX,negative
171929.0,19 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-11-14 07:35:00-05:00,BLRX,neutral
171930.0,9 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-11-13 07:22:00-05:00,BLRX,neutral
171931.0,BioLine Rx Q3 EPS $(0.03) Beats $(0.64) Estimate,2019-11-11 07:16:00-05:00,BLRX,neutral
171932.0,BioLineRx Announces Data Showing BL-8040 In Combination With KEYTRUDA Shows Clinical Activity In Heavily Pretreated Metastatic Pancreatic Cancer Patients,2019-11-05 09:06:00-05:00,BLRX,negative
171933.0,BioLineRx Highlights Presentation Of Data From From Triple Combination Of BL-8040 Anti PD-1 And Chemotherapy Demonstrating 'Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment',2019-11-05 08:05:00-05:00,BLRX,neutral
171934.0,BioLineRx To Present Two Posters At Society For Immunotherapy of Cancer (SITC) 2019 Nov. 6-10,2019-10-31 08:15:00-04:00,BLRX,negative
171935.0,42 Biggest Movers From Yesterday,2019-10-04 04:36:00-04:00,BLRX,neutral
171936.0,"BioLineRx Announces Dosing Of First Patient In Part 2 Of Phase 1/2a Clinical Study For AGI-134, A Novel Immunotherapy For Treatment Of Solid Tumors",2019-09-25 07:00:00-04:00,BLRX,positive
171937.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,BLRX,positive
171938.0,66 Biggest Movers From Yesterday,2019-09-04 05:07:00-04:00,BLRX,neutral
171939.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-09-03 12:34:00-04:00,BLRX,neutral
171940.0,32 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-03 08:42:00-04:00,BLRX,neutral
171941.0,26 Stocks Moving in Tuesday's Pre-Market Session,2019-09-03 08:09:00-04:00,BLRX,neutral
171942.0,BioLineRx Successfully Completes Dose-Escalation Part Of Phase 1/2a Clinical Study For AGI-134 Immunotherapy For Treatment Of Solid Tumors,2019-09-03 07:04:00-04:00,BLRX,positive
171943.0,"The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2",2019-08-09 07:19:00-04:00,BLRX,negative
171944.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,BLRX,neutral
171945.0,Stocks That Fell Through 52-Week Lows Wednesday,2019-08-07 14:22:00-04:00,BLRX,negative
171946.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,BLRX,neutral
171947.0,BioLine Rx Q2 EPS $(0.04) Beats $(0.63) Estimate,2019-08-06 08:04:00-04:00,BLRX,neutral
171948.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,BLRX,neutral
171949.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,BLRX,neutral
171950.0,BioLineRx Announces Change In Ratio Of American Depositary Shares To Ordinary Shares,2019-06-28 16:02:00-04:00,BLRX,positive
171951.0,"The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer",2019-06-04 07:45:00-04:00,BLRX,negative
171952.0,BioLineRx Ltd. Shares Q1 EPS $(0.06) Misses $(0.05) Estimate,2019-05-14 07:05:00-04:00,BLRX,positive
171953.0,BioLineRx On Track For Phase 2 Data Read-Outs In Pancreatic Cancer And Consolidation AML By Year-End 2019,2019-05-14 07:05:00-04:00,BLRX,positive
171954.0,"BioLine RX shares are trading higher after the company announced FDA approval of its Investigational New Drug (IND) application for AGI-134,  a novel immunotherapy anti-cancer vaccine for solid tumors.",2019-05-07 09:36:00-04:00,BLRX,positive
171955.0,"BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors",2019-05-07 07:15:00-04:00,BLRX,positive
171956.0,BioLineRx Announces FDA Approval of its Investigational New Drug Application for AGI-134,2019-05-07 07:13:00-04:00,BLRX,positive
171957.0,BioLine Rx FY18 EPS $(0.21) vs $(0.27) YoY,2019-03-28 07:13:00-04:00,BLRX,neutral
171958.0,BioLine Rx shares are trading higher after the company reported positive data from its Phase 3 GENESIS trial for BL-8040 in multiple myeloma patients.,2019-03-27 09:48:00-04:00,BLRX,positive
171959.0,BioLineRx Reports HSCs Mobilized By BL-8040 In Combo With Granulocyte Colony-Stimulating Factor Were Successfully Engrafted In All 11 Patients Participating In Part 1 Of Trial,2019-03-27 07:02:00-04:00,BLRX,positive
171960.0,"The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs",2019-02-08 09:17:00-05:00,BLRX,negative
171961.0,50 Biggest Movers From Yesterday,2019-02-06 05:03:00-05:00,BLRX,neutral
171962.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; M/I Homes Shares Spike Higher,2019-02-05 14:40:00-05:00,BLRX,negative
171963.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-02-05 12:35:00-05:00,BLRX,neutral
171964.0,Mid-Day Market Update: Estee Lauder Jumps On Upbeat Earnings; Opko Health Shares Slide,2019-02-05 12:01:00-05:00,BLRX,positive
171965.0,Mid-Morning Market Update: Markets Open Higher; Archer Daniels Midland Earnings Miss Views,2019-02-05 10:12:00-05:00,BLRX,negative
171966.0,BioLineRx Prices 28M Share Offering Of ADSs And Warrants At $0.55/Unit,2019-02-05 09:01:00-05:00,BLRX,positive
171967.0,BioLine Rx shares are trading lower after the company announced a proposed offering for its American depository shares and warrants.,2019-02-05 08:46:00-05:00,BLRX,positive
171968.0,32 Stocks Moving In Tuesday's Pre-Market Session,2019-02-05 07:53:00-05:00,BLRX,neutral
171969.0,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",2019-02-05 07:47:00-05:00,BLRX,positive
171970.0,56 Biggest Movers From Yesterday,2019-02-05 04:26:00-05:00,BLRX,neutral
171971.0,"BioLineRx 6-K Shows Co. Commenced Offering OF ADSs, No Size Disclosed",2019-02-04 16:40:00-05:00,BLRX,negative
171972.0,Mid-Afternoon Market Update: Dow Rises 100 Points; Maxwell Technologies Shares Jump Following Tesla Deal,2019-02-04 14:43:00-05:00,BLRX,positive
171973.0,35 Stocks Moving In Monday's Mid-Day Session,2019-02-04 12:22:00-05:00,BLRX,neutral
171974.0,22 Stocks Moving In Monday's Pre-Market Session,2019-02-04 07:59:00-05:00,BLRX,neutral
171975.0,BioLine Receives Orphan Drug Designation From the FDA for BL-8040 for the Treatment of Pancreatic Cancer,2019-02-04 07:17:00-05:00,BLRX,negative
171976.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,BLRX,negative
171977.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,BLRX,positive
171978.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,BLRX,negative
171979.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,BLRX,positive
171980.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,BLRX,positive
171981.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,BLRX,negative
171982.0,BioLineRx Announces Initiation Of Triple Combination Arm Of Phase 2a COMBAT/KEYNOTE-202 Study In Pancreatic Cancer Under Immuno-Oncology Collaboration,2018-12-11 07:13:00-05:00,BLRX,negative
171983.0,BioLineRx Receives FDA Biological Product Designation For Novel Cancer Immunotherapy Candidate AGI-134,2018-11-20 07:16:00-05:00,BLRX,negative
171984.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018",2018-11-15 11:37:00-05:00,BLRX,negative
171985.0,"BioLineRx Ltd. - American Depositary Shares Q3 EPS $(0.06), Inline",2018-11-08 08:52:00-05:00,BLRX,positive
171986.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,BLRX,negative
171987.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,BLRX,negative
171988.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,BLRX,neutral
171989.0,"Stocks Which Set New 52-Week Low Friday, October 26th",2018-10-29 09:56:00-04:00,BLRX,negative
171990.0,58 Biggest Movers From Friday,2018-10-22 05:11:00-04:00,BLRX,neutral
171991.0,BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Showing BL-8040 Significantly Improves T-cell Infiltration Into the Tumor and Reduces Immunosuppression in the Tumor Microenvironment at ESMO 2018,2018-10-20 16:16:00-04:00,BLRX,negative
171992.0,42 Stocks Moving In Friday's Mid-Day Session,2018-10-19 12:53:00-04:00,BLRX,neutral
171993.0,22 Stocks Moving In Friday's Pre-Market Session,2018-10-19 08:13:00-04:00,BLRX,neutral
171994.0,UPDATE: BioLineRx Says 'Triple combination expansion cohort (BL-8040 + KEYTRUDA® (pembrolizumab) + chemotherapy) to commence by year-end',2018-10-19 07:07:00-04:00,BLRX,neutral
171995.0,UPDATE: BioLineRx On Phase 2a COMBAT/KEYNOTE-202 Study: 'Encouraging results support further development of combination and expansion of collaboration',2018-10-19 07:06:00-04:00,BLRX,positive
171996.0,BioLineRx Reports Top-Line Results From Phase 2a COMBAT/KEYNOTE-202 Study In Pancreatic Cancer: Combo Showed 'encouraging disease control and overall survival in patients with metastatic pancreatic cancer',2018-10-19 07:06:00-04:00,BLRX,negative
171997.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",2018-10-14 13:21:00-04:00,BLRX,neutral
171998.0,"Stocks Which Set New 52-Week High Yesterday, October 4th",2018-10-05 09:20:00-04:00,BLRX,neutral
171999.0,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",2018-10-05 08:35:00-04:00,BLRX,positive
172000.0,"BioLineRx Raises Stake In Its Oncology Platform, BL-8040, From 60% To 80%",2018-10-03 06:04:00-04:00,BLRX,neutral
172001.0,Bioline Rx Q2 EPS $(0.05) Beats $(0.06) Estimate,2018-08-13 07:06:00-04:00,BLRX,neutral
172002.0,BioLineRx Reports The First 11 Patients In BL-8040 In Comibnation With Standard Treatment Is Safe An Tolerable And That 9/11 Patients Reached Primary Endpoint,2018-08-07 07:07:00-04:00,BLRX,positive
172003.0,"BioLineRx Initiates Phase 1/2a Clinical Study For AGI-134, A Novel Immunotherapy For Treatment Of Solid Tumors",2018-08-01 07:03:00-04:00,BLRX,positive
172004.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-30 09:05:00-04:00,BLRX,neutral
172005.0,BioLineRx Expands its Immuno-Oncology Collaboration in Pancreatic Cancer with Merck,2018-07-30 07:13:00-04:00,BLRX,negative
172006.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,BLRX,neutral
172007.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-07-08 19:16:00-04:00,BLRX,neutral
172008.0,BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients,2018-06-18 07:05:00-04:00,BLRX,positive
172009.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,BLRX,neutral
172010.0,BioLineRx Ltd. - American Depositary Shares Q1 EPS $(0.06) Beats $(0.07) Estimate,2018-05-22 07:06:00-04:00,BLRX,positive
172011.0,"Earnings Scheduled For May 22, 2018",2018-05-22 04:16:00-04:00,BLRX,neutral
172012.0,BioLineRx Claims BL-8040 In Combination With Cytarabine Showed Significantly Improved Overall Survival Compared With Historical Data,2018-05-17 09:17:00-04:00,BLRX,positive
172013.0,41 Biggest Movers From Yesterday,2018-05-17 04:32:00-04:00,BLRX,neutral
172014.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-05-16 12:39:00-04:00,BLRX,neutral
172015.0,BioLine Rx Shares Up 12.3% Premarket After Co. Received Grant Of European Patent Covering Use Of BL-8040 With Cytarabine For Treating Acute Myeloid Leukemia,2018-05-16 09:26:00-04:00,BLRX,positive
172016.0,Benzinga Pro's 5 Stocks To Watch Today,2018-05-16 09:05:00-04:00,BLRX,neutral
172017.0,BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia,2018-05-16 07:00:00-04:00,BLRX,positive
172018.0,BioLineRx Reports Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors,2018-03-26 07:04:00-04:00,BLRX,positive
172019.0,"BioLineRx Reports FY EPS $(0.27) vs $(0.28) Est., No Sales",2018-03-06 07:13:00-05:00,BLRX,negative
172020.0,BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells,2018-01-23 08:08:00-05:00,BLRX,negative
172021.0,UPDATE: BioLineRx Says BL-8040 'Data to be presented at the upcoming ASCO-GI conference; topline clinical results expected by H2 2018 as planned',2018-01-17 07:07:00-05:00,BLRX,neutral
172022.0,BioLineRx Reports Partial Monotherapy Results From Phase 2a COMBAT Study In Pancreatic Cancer: 'BL-8040 monotherapy resulted in increased infiltration of T cells into tumor',2018-01-17 07:06:00-05:00,BLRX,negative
172023.0,"5 Stocks To Watch For December 29, 2017",2017-12-29 04:10:00-05:00,BLRX,neutral
172024.0,BioLineRx F-3 Filing Shows Registration For $150M Mixed Securities Shelf Offering,2017-12-28 16:37:00-05:00,BLRX,positive
172025.0,35 Stocks Moving In Thursday's Pre-Market Session,2017-12-21 08:00:00-05:00,BLRX,neutral
172026.0,BioLineRx Reports Initiation Of Phase 3 GENESIS Trial In Stem-Cell Mobilization For Autologous Transplantation In Multiple Myeloma Patients,2017-12-21 07:01:00-05:00,BLRX,neutral
172027.0,"Oppenheimer Out Positive On BioLineRx, Says That 38% Response Rate Reported At ASH 2016 May Now Be Translating Into Survival Benefit For Patients; Believes 11.1 Median Overall Survival Observed In Cohort Is Respectable; Reiterates Outperform and $3 PT",2017-12-04 11:22:00-05:00,BLRX,positive
172028.0,30 Stocks Moving In Monday's Pre-Market Session,2017-12-04 08:12:00-05:00,BLRX,neutral
172029.0,BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML,2017-12-04 07:09:00-05:00,BLRX,positive
172030.0,"BioLineRx Reports Q4 EPS $(0.07) vs $(0.09) Est., No Sales",2017-11-21 07:05:00-05:00,BLRX,negative
172031.0,BioLineRx Shares Down 2% Despite Earlier News Co. To Give Oral Presentation At ASH Showing Data Supporting BL-8040 As Robust Mobilizer Of HSC Associated With Long-Term Engraftment,2017-11-02 10:00:00-04:00,BLRX,positive
172032.0,BioLine RX Reports At-The-Market Sales Agreement Related To Co.'s ADS's of Up To $30M,2017-10-31 17:10:00-04:00,BLRX,positive
172033.0,BioLineRx Reports Initiation Of Phase 1b/2 Trial For BL-8040 In Gastic Cancer Under Immunotherapy Collaboration,2017-10-18 07:02:00-04:00,BLRX,negative
172034.0,BioLineRx Reports Start of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Partnership,2017-09-26 07:03:00-04:00,BLRX,positive
172035.0,"BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization, Expects Study to Begin in 2017",2017-08-21 07:05:00-04:00,BLRX,neutral
172036.0,BioLineRx Reports Q2 EPS $(0.07) vs $(0.06) Est.,2017-08-08 07:19:00-04:00,BLRX,neutral
172037.0,"Oppenheimer Initiates Coverage On BioLineRx Ltd. - American Depositary Shares with Outperform Rating, Announces $3.00 Price Target",2017-08-04 08:05:00-04:00,BLRX,positive
172038.0,"BioLineRx Reports Added, Direct $9.6M Investment From BVF Partners",2017-07-26 07:28:00-04:00,BLRX,neutral
172039.0,Companies Holding Shareholder Meetings Today Include BioLineRX and Fortuna Silver Mines,2017-07-05 08:18:00-04:00,BLRX,neutral
172040.0,BioLineRx Reports Q1 EPS $(0.08) vs $(0.06) Est.,2017-05-25 07:10:00-04:00,BLRX,neutral
172041.0,"Benzinga's Top Upgrades, Downgrades For May 18, 2017",2017-05-18 09:24:00-04:00,BLRX,positive
172042.0,Maxim Group Upgrades BioLineRx Ltd. - American Depositary Shares to Buy,2017-05-18 07:38:00-04:00,BLRX,positive
172043.0,Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher,2017-03-31 14:46:00-04:00,BLRX,positive
172044.0,15 Biggest Mid-Day Losers For Friday,2017-03-31 12:41:00-04:00,BLRX,negative
172045.0,Mid-Day Market Update: Sorl Auto Parts Rises After Q4 Results; Bioline RX Shares Drop,2017-03-31 12:03:00-04:00,BLRX,neutral
172046.0,Mid-Morning Market Update: Markets Edge Lower; BlackBerry Earnings Top Views,2017-03-31 10:11:00-04:00,BLRX,negative
172047.0,BioLineRx Prices 29.4M ADS At $0.85/ADS,2017-03-31 08:27:00-04:00,BLRX,neutral
172048.0,18 Stocks Moving In Friday's Pre-Market Session,2017-03-31 08:26:00-04:00,BLRX,neutral
172049.0,BioLineRx Reports Underwritten Public Offering Of American Depositary SHares,2017-03-30 16:03:00-04:00,BLRX,positive
172050.0,"BioLineRx FY 2016 EPS $(0.28) vs $(0.08) Est, No Sales",2017-03-23 08:05:00-04:00,BLRX,negative
172051.0,BioLineRx Announces Acquisition of Agalimmune Ltd. For $6M Upfront Payment Compromised Of $3M Cash And Remainder In BioLineRx Shares,2017-03-23 07:03:00-04:00,BLRX,positive
172052.0,BioLineRx Says It Expects Top-Line Results For BL-8040 By End Of 2017,2017-03-20 07:08:00-04:00,BLRX,neutral
172053.0,"Rodman & Renshaw Initiates Coverage On BioLineRx Ltd. at Buy, $3 Price Target",2017-02-13 09:54:00-05:00,BLRX,neutral
172054.0,BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA,2017-01-17 07:05:00-05:00,BLRX,neutral
172055.0,15 Biggest Mid-Day Gainers For Monday,2016-12-05 12:48:00-05:00,BLRX,neutral
172056.0,18 Stocks Moving In Monday's Pre-Market Session,2016-12-05 08:29:00-05:00,BLRX,neutral
172057.0,BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016,2016-12-05 07:05:00-05:00,BLRX,positive
172058.0,BioLineRx Signs Exclusive Agreement With Yissum Research Development Company,2016-11-21 07:06:00-05:00,BLRX,positive
172059.0,BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016,2016-11-03 09:03:00-04:00,BLRX,positive
172060.0,BioLineRx Regains Nasdaq $1 Minimum Bid Price Requirement,2016-10-06 07:03:00-04:00,BLRX,neutral
172061.0,"BioLineRx Reports Acceptance of BL-8040 Abstracts for Oral, Poster Presentations at ASH Meeting",2016-10-05 07:01:00-04:00,BLRX,positive
172062.0,18 Biggest Mid-Day Gainers For Friday,2016-09-23 12:39:00-04:00,BLRX,neutral
172063.0,Mid-Day Market Update: Twitter Surges On Takeover Rumor; Enphase Energy Shares Drop,2016-09-23 12:03:00-04:00,BLRX,positive
172064.0,Mid-Morning Market Update: Markets Open Lower; Finish Line Sales Beat Views,2016-09-23 10:12:00-04:00,BLRX,negative
172065.0,BioLineRx Reports In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration,2016-09-23 07:01:00-04:00,BLRX,negative
172066.0,BioLineRx Reports Start of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA for Treatment of Pancreatic Cancer,2016-09-20 07:01:00-04:00,BLRX,negative
172067.0,"BioLineRx Phase 2a Trial Shows Complete Remission Rate Was 38% In 2 Cycles of BL-8040 Treatment, 1.5mg/kg Dose Selected For Expansion Phase Of Study Showed Complete Remission Rate Of 41%",2016-09-08 07:05:00-04:00,BLRX,neutral
172068.0,18 Biggest Mid-Day Gainers For Wednesday,2016-09-07 12:58:00-04:00,BLRX,neutral
172069.0,22 Stocks Moving In Wednesday's Pre-Market Session,2016-09-07 08:28:00-04:00,BLRX,neutral
172070.0,BioLineRx +13.3% Preamarket @$1.02; Co Announced Collaboration to Investigate Combination of BL-8040 with Atezolizumab,2016-09-07 07:41:00-04:00,BLRX,neutral
172071.0,BioLineRx To Collaborate With Roche on Several Phase 1b Studies,2016-09-07 07:03:00-04:00,BLRX,neutral
172072.0,"BioLineRx, I-Bridge Capital Establish a New Drug Development Joint Venture in China",2016-08-25 07:12:00-04:00,BLRX,neutral
172073.0,Maxim Group Downgrades BioLine Rx to Hold,2016-08-12 06:31:00-04:00,BLRX,neutral
172074.0,BioLineRx Reports Q2 EPS $(0.09) vs $(0.07) Est.,2016-08-11 07:17:00-04:00,BLRX,neutral
172075.0,BioLineRx Reports Q2 EPS $(0.07) vs. Est. $(0.07),2016-08-11 07:16:00-04:00,BLRX,neutral
172076.0,BioLineRx Names Philip Serlin CEO,2016-08-11 06:47:00-04:00,BLRX,neutral
172077.0,BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer,2016-08-08 07:08:00-04:00,BLRX,negative
172078.0,BioLineRx Reports Regulatory Submissions for Phase 2a Trial of BL-8040 in Combo with KEYTRUDA for Treatment of Pancreatic Cancer,2016-06-28 07:07:00-04:00,BLRX,negative
172079.0,BioLineRx Reports Q1 EPS $(0.064) vs $(0.101) in Same Qtr. Last Year,2016-05-17 08:09:00-04:00,BLRX,neutral
172080.0,"Earnings Scheduled For May 17, 2016",2016-05-17 04:05:00-04:00,BLRX,neutral
172081.0,10 Stocks Moving In Monday's Pre-Market Session,2016-04-04 08:20:00-04:00,BLRX,neutral
172082.0,BioLineRx +13% Premarkrt @$1.11 as Co Reports Novel Treatment for Non-Surgical Removal of Skin Lesions Received CE Mark Approval,2016-04-04 07:19:00-04:00,BLRX,positive
172083.0,BioLineRx Reports Novel Treatment for Non-Surgical Removal of Skin Lesions Received CE Mark Approval,2016-04-04 07:06:00-04:00,BLRX,positive
172084.0,"BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML, Identifies Future Biomarker",2016-03-29 07:02:00-04:00,BLRX,positive
172085.0,BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment,2016-03-23 07:00:00-04:00,BLRX,positive
172086.0,BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment,2016-01-25 07:01:00-05:00,BLRX,neutral
172087.0,"BioLineRx, MSD Investigate Combination of Keytruda And BL-8040 In Pancreatic Cancer",2016-01-12 07:03:00-05:00,BLRX,negative
172088.0,BioLineRx Reports Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment,2015-12-14 07:02:00-05:00,BLRX,positive
172089.0,BioLineRx Reports Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions,2015-11-23 07:01:00-05:00,BLRX,negative
172090.0,BioLine RX Reports Q3 EPS $(0.02) vs Est $(0.08),2015-11-16 07:01:00-05:00,BLRX,neutral
172091.0,"Earnings Scheduled For November 16, 2015",2015-11-16 04:01:00-05:00,BLRX,neutral
172092.0,BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AML,2015-11-05 09:00:00-05:00,BLRX,positive
172093.0,"BioLineRx Reports Regulatory Submission fo Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome, Aplastic Anemia",2015-09-10 07:01:00-04:00,BLRX,positive
172094.0,BioLineRx to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York,2015-09-03 07:04:00-04:00,BLRX,neutral
172095.0,BioLineRx Reports Beginning of Phase 2b Trial for Novel AML Consolidation Treatment,2015-08-17 07:03:00-04:00,BLRX,positive
172096.0,"Market Update: Monday's Mid-Day Movers, China's Stock Market Crash And More",2015-07-27 12:36:00-04:00,BLRX,negative
172097.0,Morning Market Losers,2015-07-27 09:50:00-04:00,BLRX,negative
172098.0,BioLineRx Investors: Expect 'Pivotal' Data In Next Few Weeks,2015-07-16 09:53:00-04:00,BLRX,neutral
172099.0,"JP Morgan: BioLineRx Will Outperform, Is Worth $5/Share On 'Promising Technology'",2015-06-22 09:54:00-04:00,BLRX,positive
172100.0,Benzinga's Top Initiations,2015-06-22 09:27:00-04:00,BLRX,positive
172101.0,"JMP Securities Initiates Coverage on Bioline Rx at Outperform, Announces $5.00 PT",2015-06-22 07:52:00-04:00,BLRX,positive
172102.0,JP Morgan Initiates Bioline RX With Market Outperform,2015-06-22 07:11:00-04:00,BLRX,positive
172103.0,"JP Morgan Initiates Coverage on Bioline Rx at Market Outperform, Announces $5.00 PT",2015-06-22 06:58:00-04:00,BLRX,positive
172104.0,BioLineRx Says Will Present Successful Results of Phase 1/2 Study of Novel Celiac Treatment,2015-06-17 07:01:00-04:00,BLRX,positive
172105.0,"BioLineRx Presents Positive Safety, Efficacy Results for Novel Stem-Cell Mobilization Treatment at European Hematology Association Conference",2015-06-15 07:06:00-04:00,BLRX,positive
172106.0,Research Underlying BioLineRx's Treatment of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award,2015-06-03 07:00:00-04:00,BLRX,positive
172107.0,BioLineRx Reports Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions,2015-06-01 07:04:00-04:00,BLRX,positive
172108.0,"BioLineRx Announces Will Present Safety, Efficacy Clinical Data for Novel Stem Cell Mobilization Treatment at EHA",2015-05-27 07:23:00-04:00,BLRX,positive
172109.0,BioLine Reports Q1 Loss $0.01 Vs Exp Loss $0.06,2015-05-18 07:02:00-04:00,BLRX,negative
172110.0,"Earnings Scheduled For May 18, 2015",2015-05-18 04:05:00-04:00,BLRX,neutral
172111.0,Analysts Like Bioline RX After Trial Hits 'Expansion Stage',2015-05-05 12:39:00-04:00,BLRX,positive
172112.0,BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for AML,2015-05-04 07:10:00-04:00,BLRX,positive
172113.0,BioLineRx Begins Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia,2015-05-04 07:00:00-04:00,BLRX,positive
172114.0,5 Biotech Stocks Roth Capital Analysts Are Watching,2015-04-08 12:21:00-04:00,BLRX,neutral
172115.0,BioLineRx's BL-9020 for Type 1 Diabetes Effective in Preclinical Trials,2015-03-11 07:03:00-04:00,BLRX,positive
172116.0,Morning Market Gainers,2015-03-09 09:43:00-04:00,BLRX,neutral
172117.0,Benzinga's Top #PreMarket Gainers,2015-03-09 08:09:00-04:00,BLRX,positive
172118.0,BioLineRx Shares Rise 6.5% Premarket; Co Presenting Tuesday at Roth Conference,2015-03-09 06:37:00-04:00,BLRX,positive
172119.0,Morning Market Losers,2015-03-06 09:51:00-05:00,BLRX,negative
172120.0,BioLineRx Files Regulatory Submission for Phase 2b Trial of BL-8040,2015-03-02 07:12:00-05:00,BLRX,neutral
172121.0,BioLineRx Announces Completion of Enrollment in CE Mark Registration Trial of BL-1040,2015-01-14 08:17:00-05:00,BLRX,neutral
172122.0,Novartis Reports 12.8% Passive Stake in BioLineRx as of December 16,2014-12-22 06:09:00-05:00,BLRX,positive
172123.0,Morning Market Movers,2014-12-16 09:42:00-05:00,BLRX,neutral
172124.0,Benzinga's Top #PreMarket Gainers,2014-12-16 08:05:00-05:00,BLRX,positive
172125.0,"UPDATE: Bioline RX Said Novartis Made $10M Initial Investment for ~12.8% of Co., Has Option to Pay $5M Fee, Could Fund 50% of Development Costs",2014-12-16 07:49:00-05:00,BLRX,negative
172126.0,UPDATE: BioLine RX Shares Rise 20% Premarket on Announcement of  Strategic Collaboration Agreement With Novartis,2014-12-16 07:47:00-05:00,BLRX,positive
172127.0,Morning Market Movers,2014-12-08 09:44:00-05:00,BLRX,neutral
172128.0,BioLineRx Announces Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference,2014-12-08 07:03:00-05:00,BLRX,positive
172129.0,US Stock Futures Signal Higher Start On Wall Street,2014-10-31 07:18:00-04:00,BLRX,neutral
172130.0,BioLineRx Announces Publication of Results from Previous Phase 1/2 Trial o f BL-1040; Expecting Study Completion Mid '15,2014-10-31 07:08:00-04:00,BLRX,neutral
172131.0,BioLineRx Announces Dosing of First Patient for BL-8040's Second Indication as Novel Stem Cell Mobilization Treatment ,2014-09-03 07:05:00-04:00,BLRX,positive
172132.0,BioLineRx Receives Notice of Allowance for US Patent on BL-7010 Covering Use of Novel Polymer in Prevention of Gluten Toxicity ,2014-08-21 07:03:00-04:00,BLRX,positive
172133.0,BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment,2014-07-16 07:01:00-04:00,BLRX,neutral
172134.0,BioLine RX Shares Edge Higher Following News of Deal to Buy $20M in Shares with Lincoln Park,2014-05-30 09:28:00-04:00,BLRX,positive
172135.0,BioLineRx Announces Investigator-Initiated Study for Novel CML Treatment ,2014-04-10 07:12:00-04:00,BLRX,positive
172136.0,US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report,2014-03-14 07:25:00-04:00,BLRX,neutral
172137.0,BioLineRx Awarded US Patent Covering Use of BL-8040 in Immunotherapy ,2014-03-14 07:02:00-04:00,BLRX,positive
172138.0,"Zix Corporation, Bio Light Israeli Life Sciences, Power Solutions International, Sapiens, Cytokinetics, BioLineRx, Arotech, FX Energy, Cherokee Presenting at Roth Conference at 12:00 PM ET",2014-03-10 12:37:00-04:00,BLRX,positive
172139.0,BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment ,2014-03-10 07:02:00-04:00,BLRX,positive
172140.0,BioLineRx Receives FDA Orphan Drug Designation for BL-8040,2014-01-23 07:16:00-05:00,BLRX,neutral
172141.0,BioLineRx Presents Positive Preclinical Results of AML Treatment at ASH,2013-12-10 07:50:00-05:00,BLRX,positive
172142.0,BioLineRx Announces Positive Phase 2a Trial Results for Orally Available IBD Treatment ,2013-11-26 07:01:00-05:00,BLRX,positive
172143.0,US Stock Futures Edge Lower Ahead Of Earnings,2013-11-19 07:53:00-05:00,BLRX,negative
172144.0,BioLineRx Reports Publication of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma ,2013-11-19 07:11:00-05:00,BLRX,positive
172145.0,BioLineRx Receives Regulatory Finnish Approval for BL-7010 Phase 1/2 Safety Trial,2013-11-04 07:01:00-05:00,BLRX,positive
172146.0,BioLineRx Announces Worldwide Licensing Agreementfor BL-9020 for Treatment of Type 1 Diabetes ,2013-10-23 07:12:00-04:00,BLRX,neutral
172147.0,"BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes",2013-10-23 07:12:00-04:00,BLRX,neutral
172148.0,BioLineRx Files Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease ,2013-09-24 06:03:00-04:00,BLRX,positive
172149.0,BioLineRx Issued Notice of Allowance by USPTO for Patent on Use of BL-8020 Treatment for Hepatitis C ,2013-09-17 07:17:00-04:00,BLRX,neutral
172150.0,BioLineRx Enters into Collaboration on Hepatitis C Drug with CTTQ,2013-06-10 07:05:00-04:00,BLRX,neutral
172151.0,Bioline RX May Sell Up to $20M in ADSs,2013-05-17 12:03:00-04:00,BLRX,neutral
172152.0,A Peek Into The Market Before The Trading Starts,2013-04-17 07:47:00-04:00,BLRX,neutral
172153.0,BioLineRx Announces Positive Phase II Results for BL-7040,2013-04-17 07:07:00-04:00,BLRX,positive
172154.0,Morning Market Movers ,2013-04-10 10:05:00-04:00,BLRX,neutral
172155.0,BioLineRx Receives Regulatory Approval for Phase II Clinical Trial for BL-8040 Leukemia Treatment,2013-04-10 07:03:00-04:00,BLRX,positive
172156.0,Stocks Hitting 52-Week Lows,2013-03-20 10:22:00-04:00,BLRX,negative
172157.0,BioLineRx Shares Resume Trading Down 50+%,2013-03-20 09:50:00-04:00,BLRX,positive
172158.0,BioLineRx Shares to Resume Trading at 9:50AM EST,2013-03-20 09:46:00-04:00,BLRX,positive
172159.0,"BioLineRX Says CLARITY Trial of BL-1020 Did Not Meet Primary Efficacy Endpoint, to Discontinue Study",2013-03-20 09:01:00-04:00,BLRX,positive
172160.0,BioLine RX Halted News Pending,2013-03-20 09:00:00-04:00,BLRX,neutral
172161.0,A Peek Into The Market Before The Trading Starts,2013-03-13 07:58:00-04:00,BLRX,neutral
172162.0,BioLineRx Gets Approval from French Regulatory Authorities for Phase I/II Clinical Trial for BL-8020 for Hepatitis C ,2013-03-13 07:10:00-04:00,BLRX,positive
172163.0,BiolineRX Moves Higher; May be Related to Globes Article on Hep C Drug Development Deal,2013-03-12 13:07:00-04:00,BLRX,neutral
172164.0,BioLineRx Clarifies Interim Analysis of CLARITY Trial for BL-1020 ,2013-02-04 07:06:00-05:00,BLRX,positive
172165.0,"Benzinga's Small Cap Movers for Tuesday January 15, 2013",2013-01-15 18:16:00-05:00,BLRX,neutral
172166.0,"BioLineRx to Report Interim Results of Phase II/III Trial for Schizophrenia Drug BL-1020 During Week of March 18, 2013 ",2013-01-07 07:24:00-05:00,BLRX,neutral
172167.0,BioLineRx to Conduct Interim Analysis of Phase II/III CLARITY Trial of BL-1020 ,2012-10-24 07:52:00-04:00,BLRX,positive
172168.0,BioLineRx Announces Successful Completion of Pre-Clinical Development for BL-8020 Hepatitis C Treatment,2012-10-16 07:04:00-04:00,BLRX,positive
172169.0,BioLineRx Announces EAGLE Phase IIb Study Shows Significantly Greater Beneficial Effect of BL-1020 on Cognitive Function in Schizophrenia Patients ,2012-10-09 07:13:00-04:00,BLRX,positive
172170.0,Morning Market Movers,2012-10-03 09:47:00-04:00,BLRX,neutral
172171.0,A Peek Into The Market Before The Trading Starts,2012-09-27 08:40:00-04:00,BLRX,neutral
172172.0,BioLineRx Enters into Share Purchase Agreement with Lincoln Park Capital  for $15M of ADSs,2012-09-27 08:08:00-04:00,BLRX,positive
172173.0,BioLineRx EAGLE Study Report Results Demonstrating BL-1020's Efficacy in Improving Cognitive Function in Schizophrenia Patients ,2012-09-27 07:08:00-04:00,BLRX,positive
172174.0,BioLineRx Receives Notice of Allowance from USPTO,2012-09-24 07:10:00-04:00,BLRX,neutral
172175.0,"BioLineRx Announces Pre-clinical Results Demonstrating the Safety of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity ",2012-09-10 07:05:00-04:00,BLRX,positive
172176.0,BiolineRx Files to Offer up to $75 Million in Mixed-Securities,2012-08-10 06:59:00-04:00,BLRX,neutral
172177.0,"BioLineRx Receives Notice of Intention to Grant Additional European Patent Covering BL-1020, for the Treatment of Schizophrenia   ",2012-07-09 07:04:00-04:00,BLRX,positive
172178.0,BioLineRx Announces Receipt of Two Notices of Allowance from USPTO for Patents Covering BL-1021,2012-06-05 07:01:00-04:00,BLRX,neutral
172179.0,"BioLineRx Receives Approval for Commencing Phase II Clinical Trial of BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease",2012-03-05 07:00:00-05:00,BLRX,positive
172180.0,"Financial Breakfast: Morning News Summary for February 29, 2012",2012-02-29 07:23:00-05:00,BLRX,neutral
172181.0,BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BCM,2012-02-29 07:05:00-05:00,BLRX,neutral
172182.0,From Earlier: BioLineRx Announces Publication of Pre-Clinical Results Demonstrating Efficacy of BL-7010,2012-02-21 08:58:00-05:00,BLRX,neutral
172183.0,BioLineRx to Place $15 Million in Securities with Institutional Investors ,2012-02-16 07:01:00-05:00,BLRX,positive
172184.0,Thinly Traded BioLineRx Shares Move on Hepatitis C Deal,2012-02-07 01:06:00-05:00,BLRX,positive
172185.0,BioLineRx Rises 17% on Licensing Agreement,2012-02-06 08:46:00-05:00,BLRX,positive
172186.0,"Financial Breakfast: Morning News Summary for February 06, 2012",2012-02-06 07:27:00-05:00,BLRX,neutral
172187.0,BioLineRx In-Licenses Second Oral Hepatitis C Treatment  ,2012-02-06 07:06:00-05:00,BLRX,neutral
172188.0,Hepatitis C Pill Race Makes BioLineRx a Buyout Target: Israel Overnight -Bloomberg,2012-01-25 07:53:00-05:00,BLRX,neutral
172189.0,"Benzinga's Microcap Movers for Tuesday January 24, 2012",2012-01-24 22:53:00-05:00,BLRX,neutral
172190.0,BioLineRx Trading 99.1% Higher on Heavy Volume; Currently at $6.55,2012-01-24 12:46:00-05:00,BLRX,neutral
172191.0,BioLineRx Trading 71.1% Higher on Heavy Volume; Currently at $5.63,2012-01-24 10:39:00-05:00,BLRX,neutral
172192.0,"BioLineRX Deal With Genoscience, Key Personnel All Under 35-Years Old, Shares Moving Lower",2012-01-24 10:36:00-05:00,BLRX,neutral
172193.0,BioLineRx Surges after Hep C License Agreement,2012-01-24 10:23:00-05:00,BLRX,positive
172194.0,BioLineRx Rises 58% on Hep C Licensing Agreement,2012-01-24 09:37:00-05:00,BLRX,positive
172195.0,BioLineRx Rises 16% on Licensing Agreement,2012-01-24 08:37:00-05:00,BLRX,positive
172196.0,"BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C   ",2012-01-24 07:00:00-05:00,BLRX,positive
172197.0,BioLineRx Announces Initiation of CE Mark Registration Trial for BCM,2012-01-03 07:05:00-05:00,BLRX,neutral
172198.0,BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen   ,2011-12-13 06:53:00-05:00,BLRX,positive
172199.0,BioLineRx Announces Positive Final Results from Phase Ia Clinical Trial of BL-1021 for Neuropathic Pain   ,2011-12-06 07:01:00-05:00,BLRX,positive
172200.0,"Financial Breakfast: Morning News Summary for November 22, 2011",2011-11-22 07:42:00-05:00,BLRX,neutral
172201.0,BioLineRx Announces Receipt of Approval in India to Commence Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of Schizophrenia   ,2011-11-22 07:02:00-05:00,BLRX,positive
172202.0,BioLineRx to Present Data from Phase IIb Trial of BL-1020 ,2011-09-27 07:05:00-04:00,BLRX,neutral
172203.0,"BioLineRx Announces European Confirmation of Medical Device Regulatory Pathway for BL-5010, for Non-surgical Removal of Skin Lesions   ",2011-09-15 07:01:00-04:00,BLRX,neutral
172204.0,Morning Market Movers,2011-09-13 09:55:00-04:00,BLRX,neutral
172205.0,BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain   ,2011-09-13 07:00:00-04:00,BLRX,positive
172206.0,Morning Market Losers,2011-09-07 09:51:00-04:00,BLRX,negative
172207.0,"BioLineRx In-Licenses BL-7050, a Novel, Orally-Available Molecule for the Treatment of Neuropathic and Inflammatory Pain   ",2011-09-07 07:02:00-04:00,BLRX,negative
172208.0,BioLineRx ADRs Begin Trading on NASDAQ  ,2011-07-25 07:06:00-04:00,BLRX,neutral
